FDA Approved: DEPAKOTE ER — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Depakote ER (divalproex sodium) submitted by AbbVie, expanding the NDA with additional regulatory authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy
• Migraine

Drugs mentioned

• DEPAKOTE ER (DIVALPROEX SODIUM)

Snippet

SUPPL AP for DEPAKOTE ER (DIVALPROEX SODIUM)